McSheehy P - Search Results

1

Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).

Genoud V, Espinoza FI, Marinari E, Rochemont V, Dietrich PY, McSheehy P, Bachmann F, Lane HA, Walker PR. Genoud V, et al. Among authors: mcsheehy p. JCI Insight. 2021 Sep 22;6(18):e142980. doi: 10.1172/jci.insight.142980. JCI Insight. 2021. PMID: 34403371 Free PMC article.

2

Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.

Burgenske DM, Talele S, Pokorny JL, Mladek AC, Bakken KK, Carlson BL, Schroeder MA, He L, Hu Z, Gampa G, Kosel ML, Decker PA, Kitange GJ, Schmitt-Hoffmann A, Bachmann F, Vaubel RA, Eckel-Passow JE, Giannini C, McSheehy P, Lane HA, Elmquist WF, Sarkaria JN. Burgenske DM, et al. Among authors: mcsheehy p. Neuro Oncol. 2022 Mar 12;24(3):384-395. doi: 10.1093/neuonc/noab162. Neuro Oncol. 2022. PMID: 34232318 Free PMC article.

3

Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.

O'Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA. O'Reilly T, et al. Among authors: mcsheehy pm. Anticancer Drugs. 2011 Jan;22(1):58-78. doi: 10.1097/CAD.0b013e3283400a20. Anticancer Drugs. 2011. PMID: 20890178

4

Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.

Braun S, McSheehy P, Litherland K, McKernan P, Forster-Gross N, Bachmann F, El-Shemerly M, Dimova-Dobreva M, Polyakova I, Häckl M, Zhou P, Lane H, Kellenberger L, Engelhardt M. Braun S, et al. Among authors: mcsheehy p. Expert Opin Investig Drugs. 2021 Nov;30(11):1071-1080. doi: 10.1080/13543784.2021.1995355. Epub 2021 Nov 9. Expert Opin Investig Drugs. 2021. PMID: 34698609 Review.

5

Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.

O'Reilly T, Lane HA, Wood JM, Schnell C, Littlewood-Evans A, Brueggen J, McSheehy PM. O'Reilly T, et al. Cancer Chemother Pharmacol. 2011 Jan;67(1):193-200. doi: 10.1007/s00280-010-1307-z. Epub 2010 May 30. Cancer Chemother Pharmacol. 2011. PMID: 20512579

6

Probing the Effects of the FGFR-Inhibitor Derazantinib on Vascular Development in Zebrafish Embryos.

Kotini MP, Bachmann F, Spickermann J, McSheehy PM, Affolter M. Kotini MP, et al. Among authors: mcsheehy pm. Pharmaceuticals (Basel). 2020 Dec 30;14(1):25. doi: 10.3390/ph14010025. Pharmaceuticals (Basel). 2020. PMID: 33396726 Free PMC article.

7

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T. Lane HA, et al. Among authors: mcsheehy pm. Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17. Clin Cancer Res. 2009. PMID: 19223496

8

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G. Traxler P, et al. Among authors: mcsheehy p. Cancer Res. 2004 Jul 15;64(14):4931-41. doi: 10.1158/0008-5472.CAN-03-3681. Cancer Res. 2004. PMID: 15256466

9

Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents.

O'Reilly T, McSheehy PM, Kawai R, Kretz O, McMahon L, Brueggen J, Bruelisauer A, Gschwind HP, Allegrini PR, Lane HA. O'Reilly T, et al. Among authors: mcsheehy pm. Cancer Chemother Pharmacol. 2010 Mar;65(4):625-39. doi: 10.1007/s00280-009-1068-8. Epub 2009 Sep 27. Cancer Chemother Pharmacol. 2010. PMID: 19784839

10

Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET.

Honer M, Ebenhan T, Allegrini PR, Ametamey SM, Becquet M, Cannet C, Lane HA, O'Reilly TM, Schubiger PA, Sticker-Jantscheff M, Stumm M, McSheehy PM. Honer M, et al. Transl Oncol. 2010 Aug 1;3(4):264-75. doi: 10.1593/tlo.10127. Transl Oncol. 2010. PMID: 20689768 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

72 results

Search Page